Deferiprone,
does it really help with Noninferior chelation success versus deferasirox in pediatric transfusion-dependent hemoglobinopathy with iron overload?
research showsThe grade is C. DEEP-2 prespecified a per-protocol primary analysis of 271 participants. Success on serum ferritin and age-dependent cardiac MRI T2* criteria occurred in 69/125 (55.2%) with deferiprone versus 80/146 (54.8%) with deferasirox. The 0.4-point difference had a 95% CI of -11.9 to 12.6, whose lower bound exceeded the prespecified -12.5-point noninferiority margin. However, laboratory and imaging surrogates, an active-control noninferiority design, and large post-randomization exclusion give C with 54 points.
ads claimSaying that deferiprone is as effective as deferasirox must be limited to meeting the 12-month ferritin and cardiac-MRI composite noninferiority margin. It does not establish equal long-term organ outcomes or survival.
Useful facts when choosing a product
- Deferiprone was given as a 75-to-100 mg/kg/day oral solution; deferasirox as 20-to-40 mg/kg/day dispersible tablets.
- Primary success used baseline-dependent ferritin criteria and, when feasible in participants older than 10, cardiac MRI T2* criteria.
- ApoPharma and Apotex relationships were disclosed, but free company supply of trial drugs was not identified.
What the research actually shows
At 21 centers in seven countries, 393 participants were randomized, 194 to deferiprone and 199 to deferasirox. The article states, ‘As per the EMA Guideline E9 the PP population was considered the primary basis for the investigation of the NI hypothesis.’ The prespecified PP1 population comprised 271 treated participants with baseline and one-year composite data and no major protocol violation, 125 versus 146. The ITT population included 390 participants receiving at least one dose, 193 versus 197, and supported consistency and missing-data analyses. Using PP as primary is appropriate in noninferiority, but excluding 122/393 (31%) was counted separately. Allocation used a centralized electronic case-report form with variable blocks, and the statistician was blinded to interventions. The EU Seventh Framework Programme funded the trial. The sponsor participated in design, data, analysis, interpretation, and writing, while the EU funder had no role. Apotex employment, former employment, patent, and consultancy relationships were disclosed, but free trial-drug supply by ApoPharma or Novartis was not identified in the article.
Why this is classified as C (54)
The prespecified noninferiority margin was met, but surrogate endpoints, active-control noninferiority, and 31% exclusion from the primary analysis give C with 54 points.
Counterpoint. C does not mean noninferiority failed. It reflects surrogate outcomes, design constraints, and missing-data sensitivity despite public funding.
Rejudgment record. Cross-check applied — Recognizes success against the prespecified -12.5-point margin in the 271-person PP primary analysis while accounting for surrogate endpoints, active-control noninferiority, and 31% primary-analysis exclusion
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Noninferior to deferasirox on 12-month iron-burden surrogates | C | Success was 55.2% versus 54.8%, with the -11.9-point lower bound above the -12.5-point margin. |
| Equivalent to deferasirox for long-term organ outcomes and survival | ? | The 12-month surrogate trial did not directly test this long-term clinical claim. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Open-label phase 3 randomized active-control noninferiority trial at 21 centers in seven countries | 197 | Public funding from the EU Seventh Framework Programme; free company supply of trial drugs was not identified | Composite success on serum ferritin and age-dependent cardiac MRI T2* criteria at 12 months | 69/125 (55.2%) versus 80/146 (54.8%); difference 0.4 points (95% CI -11.9 to 12.6); lower bound exceeded the prespecified -12.5-point margin | Publicly funded successful noninferiority evidence limited by surrogates, active control, and large PP exclusion |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Deferiprone x iron overload in pediatric transfusion-dependent hemoglobinopathy — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/deferiprone-pediatric-transfusion-dependent-haemoglobinopathy-iron-overload-noninferiority/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.